BioSenic S.A. (EBR:BIOS)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.0023
-0.0001 (-4.17%)
At close: Dec 5, 2025
-58.93%
Market Cap 1.50M
Revenue (ttm) -2.39M
Net Income (ttm) -4.00M
Shares Out 652.86M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 432,466
Average Volume 689,019
Open 0.0024
Previous Close 0.0024
Day's Range 0.0023 - 0.0024
52-Week Range 0.0012 - 0.0155
Beta -2.43
RSI 47.92
Earnings Date Apr 27, 2026

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Jean-Luc Vandebroek
Employees 7
Stock Exchange Euronext Brussels
Ticker Symbol BIOS
Full Company Profile

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.

Financial Statements

News

There is no news available yet.